Peptide · Fact sheet

Linaclotide

Also known as Linzess · guanylate cyclase-C agonist

Linaclotide is FDA approved as Linzess for specific forms of constipation and constipation-predominant irritable bowel syndrome in defined adult and pediatric age groups. It is not a systemic recovery, metabolic, or gut-healing peptide.

FDA approved for specific usesStrong human evidence for approved uses

What is Linaclotide?

Linaclotide is a 14-amino-acid peptide that activates guanylate cyclase-C on the intestinal surface and is minimally absorbed into the bloodstream.

Its local action increases intestinal fluid and can change pain signaling, which is why evidence is tied to constipation outcomes.

Benefits & claims

It demonstrates that an oral peptide can work primarily at the gut surface without needing broad systemic exposure.

The same secretory mechanism that helps constipation also explains the main risk: diarrhea and dehydration.

What the evidence supports

  • Phase 3 trials found improvements in bowel-frequency and abdominal-symptom endpoints compared with placebo.
  • Pediatric trials supported selected age-specific label expansions rather than unrestricted use in children.
Research areas
  • IBS with constipation
  • Chronic idiopathic constipation
  • Pediatric functional constipation
  • Abdominal pain and bowel symptoms
  • Other carefully defined disorders of gut sensation and motility

Dosage & frequency

Product-specific label information

Linzess has different labeled amounts by constipation diagnosis and age. The adult IBS-C amount should not be applied to every constipation population.

Linzess: adult IBS-C

Adults with irritable bowel syndrome with constipation

Amount
290 mcg
Frequency
Once daily
Route studied or labeled
Oral

Diagnosis-specific label.

Linzess: adult CIC

Adults with chronic idiopathic constipation

Amount
145 mcg; 72 mcg may be used based on presentation or tolerability
Frequency
Once daily
Route studied or labeled
Oral

Diagnosis-specific label.

Linzess: pediatric IBS-C

Patients age seven years and older with IBS-C

Amount
145 mcg
Frequency
Once daily
Route studied or labeled
Oral

Contraindicated below age two; pediatric diagnosis matters.

Linzess: pediatric functional constipation

Patients age two years and older with functional constipation

Amount
72 mcg
Frequency
Once daily
Route studied or labeled
Oral

Different pediatric constipation indication.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • The approved oral capsule acts mainly within the gut.

Interactions & precautions

  • The label states that drug-drug interaction studies have not been conducted; systemic exposure is negligible after labeled oral use.

What is still unresolved

  • Individual response and tolerability vary; the label contains diagnosis- and age-specific restrictions.

Side effects & risks

  • The label carries a boxed warning about serious dehydration risk in children younger than 2 years.
  • Severe diarrhea can occur and is the main clinically important adverse effect.
  • It is contraindicated when mechanical gastrointestinal obstruction is known or suspected.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Strong human evidence for approved uses

Multiple controlled trials and indication expansions support the labeled gastrointestinal uses. The peptide's local action and evidence do not establish general microbiome, anti-inflammatory, or wellness benefits.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 4 sourced accounts by reported effect.

Digestion: reported experiences

Negative account · personal report

Persistent diarrhea disrupted daily life

An author described about a month of bowel movements shifting from absent to substantial diarrhea. Their reply described it as annoying rather than painful.

Reported use in this account

Product
Linzess
Amount
Not specified clearly
Frequency
Not specified clearly
Route
Not specified clearly
Duration
About one month

This is one person's experience with Linzess; diagnosis, other treatments and severity were not independently checked.

Read the original account
Mixed account · personal report

Initial relief became less reliable

A person with longstanding constipation described no initial effect, then about two months of relief from bloating with loose stools, followed by much less reliable bowel movements.

Reported use in this account

Product
Linzess; the source's amount has an unresolved unit
Amount
Not specified clearly
Frequency
Daily
Route
Not specified clearly
Duration
About four months

The source's amount has an unresolved unit and is not reproduced. The fluctuating response does not establish tolerance; no clinical record or controlled comparison was supplied.

Read the original account
Positive account · personal report

Satisfied without diarrhea

A different commenter said they were pleased with Linzess and did not experience diarrhea.

Amount, frequency, route and duration could not be confirmed for this account.

This brief comment gives no duration, diagnosis or measured outcome; it does not establish typical tolerability.

Read the original account
No noticeable effect · personal report

No benefit reported

Another commenter in a constipation discussion said Linzess had done nothing for them.

Amount, frequency, route and duration could not be confirmed for this account.

The comment lacks duration, diagnosis and concurrent-treatment details.

Read the original account

Approval status

Current FDA labeling covers IBS with constipation, chronic idiopathic constipation, and pediatric functional constipation in the specific age groups listed for each indication.

Approved uses

  • The adult and age-specific pediatric constipation indications in current Linzess labeling

FDA approved for labeled constipation disorders

Linaclotide is approved under the Linzess label for specific adult and pediatric constipation-related indications. The approval is label-specific.

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Which patients will have a durable response rather than intolerable diarrhea
  • Long-term comparative effectiveness across approved constipation medicines
  • Whether other formulations can separate pain relief from secretory effects
  • Benefits outside labeled constipation disorders

Summary

Linzess is approved for specific constipation disorders, not general gut repair or optimization.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. fdaFDA prescribing information: Linzess

    Current age-specific indications, boxed warning, contraindications, and safety information.

  2. pubmedRandomized Phase 3 IBS-C trial

    Controlled trial of abdominal pain and bowel outcomes with randomized withdrawal.

  3. pubmedRandomized pediatric functional-constipation trial

    Age-specific Phase 3 evidence supporting a pediatric indication.

How we assess sources · Suggest a correction